|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2001; 38:1130-1136 © 2001 by the American College of Cardiology Foundation |
a Department of Internal Medicine II, Justus-Liebig-University, Giessen, Germany
Manuscript received December 15, 2000; revised manuscript received May 31, 2001, accepted June 19, 2001.
Reprint requests and correspondence: Dr. Horst Olschewski, Department of Internal Medicine II, Klinikstr. 36, 35392 Giessen, Germany
horst.olschewski{at}innere.med.uni-giessen.de
OBJECTIVES
The goal of this study was to assess atrial natriuretic peptide (ANP) levels during inhalation of iloprost in severe primary (PPH) and nonprimary pulmonary hypertension (NPPH).
BACKGROUND
The ANP system is activated in pulmonary hypertension and may help protect from right ventricular (RV) decompensation. It is unknown if ANP regulation is the same in severe PPH and NPPH and if the dynamic regulation is intact in a highly activated ANP system.
METHODS
In 11 patients with PPH and seven patients with NPPH, right heart catheter investigations were performed. Pulmonary and systemic artery ANP and cyclic guanosine monophosphate (cGMP) levels as well as hemodynamics were measured before and after iloprost inhalation.
RESULTS
The baseline hemodynamics of patients with PPH and patients with NPPH were comparable (mean pulmonary artery pressure [mPAP]: 61 ± 5 mm Hg vs. 52 ± 5 mm Hg, pulmonary vascular resistance [PVR]: 1,504 ± 153 dyne·s·cm–5 vs. 1,219 ± 270 dyne·s·cm–5. Atrial natriuretic peptide and cGMP levels were increased about tenfold and fivefold compared with controls in both PPH and NPPH. Iloprost inhalation significantly decreased mPAP (–9.1 ± 2.5 mm Hg vs. –7.9 ± 1.5 mm Hg), PVR (–453 ± 103 dyne·s·cm–5 vs. –381 ± 114 dyne·s·cm–5), ANP (–99 ± 63 pg/ml vs. –108 ± 47 pg/ml) and cGMP (–4.6 ± 0.9 nM vs. –4.2 ± 1.6 nM). Baseline ANP including all patients significantly correlated with PVR, right atrial pressure, cardiac index, RV ejection fraction, mixed venous oxygen saturation and cGMP.
CONCLUSIONS
The ANP system is highly activated in patients with severe PPH and NPPH. Atrial natriuretic peptide levels are significantly correlated with parameters of RV function and pre- and afterload. Iloprost inhalation causes a rapid decrease in ANP and cGMP in parallel with pulmonary vasodilation and hemodynamic improvement.
| ||||||||||||||||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Behr and J. H. Ryu Pulmonary hypertension in interstitial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Leuchte, M. El Nounou, J. C. Tuerpe, B. Hartmann, R. A. Baumgartner, M. Vogeser, O. Muehling, and J. Behr N-terminal Pro-Brain Natriuretic Peptide and Renal Insufficiency as Predictors of Mortality in Pulmonary Hypertension Chest, February 1, 2007; 131(2): 402 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Wagner, S. Buz, H. Zais, J. P. Stasch, R. Hetzer, and B. Hocher Humoral and hemodynamic responses after left ventricular assist device implantation and heart transplantation. Experimental Biology and Medicine, June 1, 2006; 231(6): 861 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Leuchte, R. A. Baumgartner, M. E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, and J. Behr Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, C. Neurohr, M. Vogeser, and J. Behr Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2368 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E Baker and R. H. Hockman Inhaled Iloprost in Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, B. Karadas, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1488 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Yap, D. Mukerjee, P. M. Timms, H. Ashrafian, and J. G. Coghlan Natriuretic Peptides, Respiratory Disease, and the Right Heart Chest, October 1, 2004; 126(4): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves End points in pulmonary arterial hypertension: the way forward Eur. Respir. J., June 1, 2004; 23(6): 947 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, I. Ding, C. Neurohr, M. Vogeser, T. Kolbe, M. Schwaiblmair, and J. Behr Clinical significance of brain natriuretic peptide in primary pulmonary hypertension J. Am. Coll. Cardiol., March 3, 2004; 43(5): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle Haemodynamic evaluation of pulmonary hypertension Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
